Net profit of Astrazeneca Pharma India rose 41.09% to Rs 54.22 crore in the quarter ended September 2025 as against Rs 38.43 crore during the previous quarter ended September 2024. Sales rose 37.03% to Rs 559.09 crore in the quarter ended September 2025 as against Rs 408.00 crore during the previous quarter ended September 2024.
| Particulars | Quarter Ended |
| Sep. 2025 | Sep. 2024 | % Var. |
| Sales | 559.09 | 408.00 | 37 |
| OPM % | 13.45 | 12.88 | - |
| PBDT | 80.68 | 60.35 | 34 |
| PBT | 78.11 | 51.03 | 53 |
| NP | 54.22 | 38.43 | 41 |